



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

Date: August 12, 2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 543434

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: SUPRIYA

Dear Sir (s),

Sub: Outcome of Board Meeting in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Friday, August 12, 2022, inter-alia, has:


1. Considered and approved the Unaudited Financial Results for the Quarter ended June 30, 2022.
2. Recommended re-appointment of M/s. Kakaria & Associates LLP, Chartered Accountants (Firm Registration No. 104558W/W100601) as the Statutory Auditors of the Company, for second term of five years from the conclusion of the ensuing 14th AGM till the conclusion of the 19th AGM to be held in the year 2027, subject to approval of the members at the ensuing 14th AGM..

The Financials Results will be published in newspapers as required under the Listing Regulations.

We hereby enclose the following:

1. Copy of the Unaudited Financial Results of the Company for the quarter ended June 30, 2022 along with the Limited Review report issued by Statutory Auditor;
2. Brief Profile of Statutory Auditor as required vide SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015;

The Meeting of the Board of Directors of the Company commenced at 06:00 p.m. and concluded at 07:00 p.m.



Corporate Office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai 400 063, Maharashtra, India.

Tel : +91 22 40332727 / 66942507 | Fax : +91 22 26860011 | GSTIN : 27AALCS8686A1ZX

CIN: L51900MH2008PLC180452 |E-mail: supriya@supriyalifescience.com |Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C., Tal.-Khed, Dist. Ratnagiri, Pin: 415 722, Maharashtra, India.

Tel: +91 2356 272299 | Fax : +91 2356 272178 | E-Mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

Kindly take the above said information on your records.

Thanking you,

Yours faithfully,

For Supriya Lifescience Limited



Shweta Singh

Company Secretary & Compliance Officer

Membership No.: A44973

Corporate Office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai 400 063, Maharashtra, India.

Tel : +91 22 40332727 / 66942507 | Fax : +91 22 26860011 | GSTIN : 27AALCS8686A1ZX

CIN: L51900MH2008PLC180452 | E-mail: supriya@supriyalifescience.com | Website: www.supriyalifescience.com

Factory

: A-5/2, Lote Parshuram Industrial Area, M.I.D.C., Tal.-Khed, Dist. Ratnagiri, Pin: 415 722, Maharashtra, India.

Tel: +91 2356 272299 | Fax : +91 2356 272178 | E-Mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE

SUPRIYA LIFESCIENCE LIMITED

CIN: L51900MH2008PLC180452


Registered Office: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063.

Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

Part I -Statement of Standalone Unaudited Financial Results for the Quarter Ended June 30, 2022

Rs. in Millions, except per share data

Particulars	Quarter ended	Quarter ended	Quarter ended	Year ended
	30-06-2022	31-03-2022	30-06-2021	31-03-2022
	Unaudited	Audited	Unaudited	Audited
Income				
Revenue from Operations	1,013.55	1,812.69	769.42	5,300.49
Other Income	23.57	38.55	19.39	75.77
Total Income	1,037.12	1,851.24	788.81	5,376.26
Expenses				
a) Cost of Materials Consumed	425.85	382.42	419.25	1,988.30
b) Purchase of Stock in Trade	-	-	-	-
c) Change in inventories of finished goods , work in progress & stock in trade.	-75.72	325.89	-23.58	-30.26
d. Employee benefit expenses	126.70	128.69	83.76	490.78
e. Finance Cost	5.81	10.17	9.74	41.98
f. Depreciation & amortisation expense	28.85	25.79	24.77	101.18
g. Other expenditure	224.26	223.46	135.46	711.82
Total Expenses	735.76	1,096.43	649.40	3,303.81
Profit/(loss) before Exceptional Items & Tax	301.36	754.81	139.41	2,072.45
Exceptional Items	-	-	-	-
Profit/(loss) before Tax	301.36	754.81	139.41	2,072.45
Tax Expense				
a) Current Tax	45.87	184.45	16.05	521.89
b) Deferred Tax	3.00	108.25	45.97	32.46
Total Tax Expense	48.87	292.70	62.02	554.35
Profit/(Loss) for the period	252.49	462.11	77.39	1,518.10
Other Comprehensive Income				
A (i) Items that will not be reclassified to profit or loss	-9.86	1.55	0.06	-4.22
(ii) Income Tax relating to items that will not be reclassified to profit or loss	2.48	-0.37	-0.02	1.08
B (i) Items that will be reclassified to profit or loss	-	-	-	-
(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-
Total Other Comprehensive Income for the period	-7.38	1.17	0.04	-3.15
Total Comprehensive Income for the period	245.11	463.28	77.43	1,514.95
Earnings per equity Share (for continuing operation):				
(1) Basic	3.14	5.74	0.96	18.86
(2) Diluted	3.14	5.74	0.96	18.86
Earnings per equity Share (for discontinued operation):				
(1) Basic	-	-	-	-
(2) Diluted	-	-	-	-
Earnings per equity Share (for discontinued & continuing operations):				
(1) Basic	3.14	5.74	0.96	18.86
(2) Diluted	3.14	5.74	0.96	18.86



Notes:-

1. The Unaudited Standalone financial results of the Company for the quarter ended June 30, 2022 have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as ammended.
2. The above Unaudited standalone financial results of the Company for the quarter ended June 30, 2022 have been reviewed by the Audit Committee on August 12, 2022 and thereafter approved by the Board of Directors at their meeting held on August 12, 2022.
3. The Statutory Auditor have submitted Limited Review Report on the above Unaudited Financial Results for Quarter ended June 30, 2022.
4. The figures of the previous periods have been regrouped/reclassified wherever considered necessary.

**For and on behalf of the board of directors of
Supriya Lifescience Limited**

**Place :- Mumbai
Date :- August 12, 2022**




**Saloni Wagh
Whole Time Director
DIN: 08491410**

KAKARIA AND ASSOCIATES LLP

CHARTERED ACCOUNTANTS

UJWAL K. KAKARIA B.Com., B.L., F.C.A.

SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A.

JAIPRAKASH H. SHETHIYA B.Com., F.C.A.

YOUR REF. :


OUR REF. :

Independent Auditor's Review Report on Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,

Board of Directors of Supriya Lifescience Limited,

1. We have reviewed the accompanying statement of unaudited financial results of **Supriya Lifescience Limited** ("the Company") for the quarter ended 30th June ,2022, ("the Statement"), being submitted by the company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing regulations")
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been compiled from the related IND AS Financial Statements which has been prepared in accordance with Indian Accounting Standards prescribed under Section 133 of the Companies Act 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and



perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 14th October, 2021 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For,
Kakaria and Associates LLP
Chartered Accountants.
FRN: 104558W/ W100601



CA. Ujwal K. Kakaria
Partner
Membership No. – 035416
Place: - Mumbai
Date: - 12/08/2022
UDIN: - 22035416AOXTAB2321



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

Brief disclosures of Statutory Auditor on reappointment as required vide SEBI Circular CIRICFDICMD/4/2015 dated September 9, 2015 has been provided below:

Name of the Statutory Auditor	M/s. Kakaria & Associates LLP, Chartered Accountants
Reason for change viz. appointment, resignation, removal, death or otherwise	M/s. Kakaria & Associates LLP , Chartered Accountants are reappointed as the Statutory Auditors of the Company, subject to approval of the members at the ensuing 14th AGM.
Date and Term of appointment	M/s. Kakaria & Associates LLP, Chartered Accountants are reappointed as the Statutory Auditors of the Company for a second term of five consecutive years i.e. to hold office from the conclusion of the 14th Annual General Meeting until the conclusion of 19th Annual General Meeting subject to the approval of the shareholders of the Company.
Brief Profile	M/s. Kakaria & Associates LLP, is a leading Chartered Accountancy firm in Mumbai, led by skilled and experienced Indian Chartered Accountants having industry experience of over a decade. The Firm provides services in the areas of Income Tax, GST, Audit & assurance, Accounts, Company secretary, Cost accountancy/audit, Finance, and Personal/corporate financial planning along with a host of other financial services with its head office at Vapi, Gujarat and branches at Mumbai, Boisar, Dahanu and Umbergaon.
Disclosure of Relationship Directors	Not Applicable



Corporate Office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai 400 063, Maharashtra, India.

Tel : +91 22 40332727 / 66942507 | Fax : +91 22 26860011 | GSTIN : 27AALCS8686A1ZX

CIN: L51900MH2008PLC180452 |E-mail: supriya@supriyalifescience.com |Website: www.supriyalifescience.com

Factory

: A-5/2, Lote Parshuram Industrial Area, M.I.D.C., Tal.-Khed, Dist. Ratnagiri, Pin: 415 722, Maharashtra, India.

Tel: +91 2356 272299 | Fax : +91 2356 272178 | E-Mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE